摘要
目的对比棘突球囊联合紫杉醇药物涂层球囊与切割球囊联合紫杉醇药物涂层球囊在冠状动脉病变中的应用效果与安全性。方法纳入2021年1月—2022年6月沧州市人民医院收治的90例冠状动脉病变患者,采用随机数字表法将患者随机分为两组,Scoring组(45例,棘突球囊联合紫杉醇药物涂层球囊治疗)和Cutting组(45例,切割球囊联合紫杉醇药物涂层球囊治疗)。主要终点指标为靶病变血管血运重建率,次要终点指标包括主要心血管事件(MACE)发生率、术后主要不良事件(MAE)发生率、无事件生存率,对比两组患者临床症状改善情况(心功能、运动能力)、生物标志物[B型钠尿肽(BNP)、白细胞介素-6(IL-6)]。结果术后Scoring组和Cutting组MACE发生率为4.44%(2/45)、17.78(8/45),IL-6分别为(18.79±3.58)pg/mL、(21.58±3.49)pg/mL,Scoring组MACE发生率、IL-6均低于Cutting组(χ^(2)=4.050、t=3.743,均P<0.05)。两组再狭窄率、血运重建率、MAE发生率、无事件生存率、美国纽约心脏病协会(NYHA)、6 min步行试验(6MWT)比较,差异均无统计学意义(均P>0.05)。结论在冠状动脉病变中,棘突球囊联合紫杉醇药物涂层球囊与切割球囊联合紫杉醇药物涂层球囊再狭窄率、血运重建率、MAE发生率、无事件生存率、临床症状改善方面差异无统计学意义,但棘突球囊联合紫杉醇药物涂层相对于切割球囊联合紫杉醇药物涂层球囊MACE发生率和IL-6更低。
Objective To compare the clinical efficacy and safety of thorn-balloon and cutting-balloon combined with paclitaxel drug-coated balloons in coronary artery lesions.Methods A total of 90 patients with coronary artery lesions treated In Cangzhou People’s Hospital from January 2021 to June 2022 were included.Patients were randomly assigned to two groups using a random number table:the Scoring group(45 cases,treated with thorn-balloon combined with paclitaxel drug-coated balloon)and the Cutting group(45 cases,treated with cutting-balloon combined with paclitaxel drug-coated balloon).The primary endpoint were restenosis rate andthe target lesion revascularization rate,secondary endpoints included the incidence of major cardiovascular events(MACE),postoperative major adverse events(MAE),and event-free survival rate.Clinical symptoms improvement(heart function,exercise capacity)and biomarkers[B-type natriuretic peptide(BNP),interleukin-6(IL-6)]were compared between the two groups.Results Postoperatively,the incidence of MACE was 4.44%(2/45)in the Scoring group and 17.78%(8/45)in the Cutting group,IL-6 levels were(18.79±3.58)pg/mL in the Scoring group and(21.58±3.49)pg/mL in the Cutting group,The incidence of MACE and IL-6 in Group Scoring were lower than that in Group Cutting(χ^(2)=4.050,t=3.743,all P<0.05).No significant differences were found between the two groups in restenosis rate,target lesion revascularization rate,MAE incidence,event-free survival rate,New York Heart Association(NYHA),6-minute walk test(6MWT)(all P>0.05).Conclusion In coronary artery lesions,thorn-balloon combined with paclitaxel drug-coated balloon and cutting-balloon combined with paclitaxel drug-coated balloon demonstrated no significant difference in restenosis rate,revascularization rate,MAE incidence,event-free survival rate,or clinical symptom improvement.However,the combination of thorn-balloon with a paclitaxel drug-coated balloon was associated with a lower incidence of MACE and reduced IL-6 levels compared to the combination of cutting-balloon with a paclitaxel drug-coated balloon.
作者
冯翔宇
赵殿儒
戈美琴
申巧丽
杜荣生
FENG Xiangyu;ZHAO Dianru;GE Meiqin;SHEN Qiaoli;DU Rongsheng(Department of Cardiology,Cangzhou People’s Hospital,Cangzhou Hebei 061000,China)
出处
《中国急救复苏与灾害医学杂志》
2025年第6期796-799,共4页
China Journal of Emergency Resuscitation and Disaster Medicine
基金
河北省自然科学基金资助项目(H2021206217)
沧州市重点研发计划项目(213106018)。
关键词
冠状动脉疾病
紫杉醇
棘突球囊
切割球囊
再狭窄
主要心血管事件
临床症状
主要不良事件
Coronary artery disease
Paclitaxel
Thorn-balloon
Cutting-balloon
Restenosis
Major cardiovascular events
Clinical symptoms
Major adverse events
